Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/120534
Title: | Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort : an Epi-IBD study |
Authors: | Burisch, Johan Chetcuti Zammit, Stefania Ellul, Pierre Turcan, Svetlana Duricova, Dana Bortlik, Martin Winther Andersen, Karina Andersen, Vibeke Kaimakliotis, Ioannis P, Fumery, Mathurin Gower-Rousseau, Corinne Girardin, Giulia Valpiani, Daniela Goldis, Adrian Brinar, Marko Čuković-Čavka, Silvija Oksanen, Pia Collin, Pekka Barros, Luisa Magro, Fernando Misra, Ravi Arebi, Naila Eriksson, Carl Halfvarson, Jonas Kievit, Hendrika Adriana Linda Pedersen, Natalia Kjeldsen, Jens Myers, Sally Sebastian, Shaji Katsanos, Konstantinos H. Christodoulou, Dimitrios K. Midjord, Jóngerð Nielsen, Kári Rubek Kiudelis, Gediminas Kupcinskas, Limas Nikulina, Inna Belousova, Elena Schwartz, Doron Odes, Selwyn Salupere, Riina Carmona, Amalia Pineda, Juan R. Vegh, Zsuzsanna Lakatos, Peter L. Langholz, Ebbe Munkholm, Pia |
Authors: | Epi-IBD group |
Keywords: | Inflammatory bowel diseases Crohn's disease Ulcerative colitis Prognosis Therapeutics |
Issue Date: | 2019 |
Publisher: | John Wiley & Sons, Inc. |
Citation: | Burisch, J., Zammit, S. C., Ellul, P., Turcan, S., Duricova, D., Bortlik, M.,...Epi‐IBD group. (2019). Disease course of inflammatory bowel disease unclassified in a European population‐based inception cohort: An Epi‐IBD study. Journal of gastroenterology and hepatology, 34(6), 996-1003. |
Abstract: | Background and Aim: A definitive diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC) is not always possible, and a proportion of patients will be diagnosed as inflammatory bowel disease unclassified (IBDU). The aim of the study was to investigate the prognosis of patients initially diagnosed with IBDU and the disease course during the following 5 years. Methods: The Epi-IBD study is a prospective population-based cohort of 1289 IBD patients diagnosed in centers across Europe. Clinical data were captured prospectively throughout the follow-up period. Results: Overall, 476 (37%) patients were initially diagnosed with CD, 701 (54%) with UC, and 112 (9%) with IBDU. During follow-up, 28 (25%) IBDU patients were changed diagnoses to either UC (n = 20, 71%) or CD (n = 8, 29%) after a median of 6 months (interquartile range: 4–12), while 84 (7% of the total cohort) remained IBDU. A total of 17 (15%) IBDU patients were hospitalized for their IBD during follow-up, while 8 (7%) patients underwent surgery. Most surgeries (n = 6, 75%) were performed on patients whose diagnosis was later changed to UC; three of these colectomies led to a definitive diagnosis of UC. Most patients (n = 107, 96%) received 5-aminosalicylic acid, while 11 (10%) patients received biologicals, of whom five remained classified as IBDU. Conclusions: In a population-based inception cohort, 7% of IBD patients were not given a definitive diagnosis of IBD after 5 years of follow-up. One in four patients with IBDU eventually was classified as CD or UC. Overall, the disease course and medication burden in IBDU patients were mild. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/120534 |
Appears in Collections: | Scholarly Works - FacM&SMed |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Disease_course_of_inflammatory_bowel_disease_unclassified_in_a_European_population_based_inception_cohort_an_Epi_IBD_study_2019.pdf Restricted Access | 396.41 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.